Gyre Therapeutics, Inc.GYRENASDAQ
Loading
EBITDA Over TimeContracting
Percentile Rank86
3Y CAGR+10.7%
Studio
Year-over-Year Change

Earnings before interest, taxes, depreciation, and amortization

3Y CAGR
+10.7%/yr
Annual compound
Percentile
P86
Within normal range
vs 3Y Ago
1.4x
Solid growth
Streak
2 yr
Consecutive declineContracting
PeriodValueYoY Change
2025$14.01M-21.4%
2024$17.82M-12.3%
2023$20.33M+96.7%
2022$10.33M+111.8%
2021$-87.64M-56.2%
2020$-56.10M-1.9%
2019$-55.03M-62.7%
2018$-33.82M-55.0%
2017$-21.82M-28.8%
2016$-16.95M-